In the world of pharmaceuticals, even slight temperature fluctuations can compromise the efficacy and safety of life-changing medications. Maintaining the highest quality standards is not just an aspiration; it's an absolute necessity.

The biopharma industry loses approximately $35 billion annually due to failures in temperature-controlled logistics, according to IQVIA Institute for Human Data Science (2019 Biopharma Cold Chain Logistics Survey Report).

Here at SkyCell, we understand the importance of ensuring the integrity of pharmaceuticals throughout the supply chain.

A new standard in excellence

For the past six years, top-3 auditor EY has confirmed that our hybrid container solutions reduce temperature excursion rates to less than 0.1%.

This year, we’ve taken another step in our pursuit of excellence.

Our excursion rate has been revealed to be less than 0.05%, setting a new standard in the pharmaceutical industry. Furthermore, SkyCell has more than 10 years of 0.0% product loss due to temperature excursions.

The key ingredients according to Nicola Caristo, Quality Lead SkyCell: “SkyCell is able to lead the industry with less than 0.05% temperature excursions because of our technology, quality systems and the quality mindset of the organisation.”

“SkyCell's technology is engineered to handle extreme temperatures and long independent runtimes (270+ hours), while also addressing critical process challenges. For instance, it avoids airport unloading through its door-to-door capabilities. This is made possible by its single pallet design, which offers greater ease of handling compared to multi-pallet solutions. Moreover, it combines hardware with software and IoT, forming what we term as S+O data.” Nico Ros, SkyCell CTO